EZ Traders Forum

[RIGATONI]

~MLHP News...


Millenia Hope Initiates W.H.O. Monitored Pediatric Anti-Malaria Trial With MMH8(TM) Malarex
MONTREAL, Feb 22, 2005 /PRNewswire via COMTEX/ --
Millenia Hope Inc., a Biotech Corporation (OTC Bulletin Board: MLHP; Berlin: MLF), announced that it has initiated a second Company sponsored trial in the Republic of Central Africa (RCA).

The 360 patient trial, is under the watchful eye of the World Health Organization, UNICEF and the Pasteur Institute, France. This trial follows the Company's recent success with three efficacy trials; on 33 adults using MMH18(TM) adult formulation and in 30 children (12-60 months) with MMH 8(TM), the pediatric formulation of MMH 18(TM) in RCA; and with Camoquin 200 as a comparator in 52 adults in Cameroon.

The new Millenia Hope trial is an extended study in the pediatric patient group, previously studied (12-60 months), with non-complicated malaria, (children with no signs of malnutrition and/or other diseases including HIV and Hepatitis). It will be carried out in three major cities in RCA.

A five-day treatment of MMH(TM) reduces the fever, in the majority of patients within three to four days and significantly decreases the parasite density per ul of blood, (from as high as 50 000 per ul to > 200) in five days. In all patients the parasite density was decreased to zero within seven days, and the disease-associated anemia improved significantly during the 14-day follow-up period.

Leonard Stella, CEO at Millenia Hope reports, "MMH Malarex(TM) has a major impact on drug-resistant strains of malaria when administered to patients in areas where these are the prevalent strains." He continued, "We are ecstatic that the WHO, UNICEF and the Pasteur Institute are monitoring this study and have approved the protocol. This is a major step forward for the Company to interest these organizations in our products."

"Millenia Hope has been engaged in the fight against malaria for more than 8 years. We have permission to sell our products in 16 countries, with three more to come," says Hugo Valente, CFO. "Our aim this year is to sell 300,000 treatments in two major markets." Malaria claims nearly 3 million lives annually and its global market is estimated at $10 billion US.

About Millenia Hope:

Millenia Hope develops innovative treatments and quality products that will increase the quality of life, provide tools in the fight against devastating diseases, and promote healthier lives. Our team is committed to research and development to deliver on global medical needs and to bring hope through healthcare solutions.

Safe Harbor Statement:

Certain statements made in this release may contain language describing the plans, goals, strategies, intentions, forecasts and expectations of Millenia Hope that may be referred to as "forward-looking statements." Several important factors could cause actual results to differ materially from those in such forward-looking statements, and Millenia Hope could encounter unanticipated obstacles and delays in developing products, service offerings and markets.

This release was issued through Major Newswire ( http://www.majornewswire.com ).

SOURCE Millenia Hope Inc.

Raymond Roy, [phone], fax, [phone], for Millenia Hope Inc.

http://www.prnewswire.com


--------------------------------------------------------------------------------

Copyright (C) 2005 PR Newswire. All rights reserved.

News provided by